Chemotherapy Extravasation: Establishing a National Benchmark for Incidence Among Cancer Centers

Clin J Oncol Nurs. 2017 Aug 1;21(4):438-445. doi: 10.1188/17.CJON.438-445.

Abstract

Background: Given the high-risk nature and nurse sensitivity of chemotherapy infusion and extravasation prevention, as well as the absence of an industry benchmark, a group of nurses studied oncology-specific nursing-sensitive indicators. .

Objectives: The purpose was to establish a benchmark for the incidence of chemotherapy extravasation with vesicants, irritants, and irritants with vesicant potential. .

Methods: Infusions with actual or suspected extravasations of vesicant and irritant chemotherapies were evaluated. Extravasation events were reviewed by type of agent, occurrence by drug category, route of administration, level of harm, follow-up, and patient referrals to surgical consultation. .

Findings: A total of 739,812 infusions were evaluated, with 673 extravasation events identified. Incidence for all extravasation events was 0.09%.

Keywords: cancer program quality; chemotherapy; extravasation; irritant; venous access; vesicant.

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Cancer Care Facilities / organization & administration*
  • Extravasation of Diagnostic and Therapeutic Materials / epidemiology*
  • Humans
  • Incidence
  • Neoplasms / drug therapy*
  • Neoplasms / nursing

Substances

  • Antineoplastic Agents